Van ECK Associates Corp Has $40.74 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Posted by Stanley Muller on Aug 30th, 2026

Van ECK Associates Corp boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 4.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 65,332 shares of the biopharmaceutical company’s stock after acquiring an additional 2,748 shares during the quarter. Van ECK Associates Corp owned 0.06% of Regeneron Pharmaceuticals worth $40,737,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Nissay Asset Management Corp Japan increased its holdings in Regeneron Pharmaceuticals by 6.1% during the 2nd quarter. Nissay Asset Management Corp Japan now owns 30,636 shares of the biopharmaceutical company’s stock worth $19,103,000 after purchasing an additional 1,767 shares in the last quarter. Kimelman & Baird LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 154.9% in the second quarter. Kimelman & Baird LLC now owns 27,671 shares of the biopharmaceutical company’s stock valued at $17,254,000 after purchasing an additional 16,815 shares in the last quarter. Strait & Sound Wealth Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 3.8% in the second quarter. Strait & Sound Wealth Management LLC now owns 714 shares of the biopharmaceutical company’s stock valued at $445,000 after purchasing an additional 26 shares in the last quarter. Rakuten Investment Management Inc. boosted its position in shares of Regeneron Pharmaceuticals by 15.6% during the second quarter. Rakuten Investment Management Inc. now owns 24,580 shares of the biopharmaceutical company’s stock valued at $15,530,000 after buying an additional 3,320 shares during the last quarter. Finally, Glenview Trust Co boosted its position in shares of Regeneron Pharmaceuticals by 11.0% during the second quarter. Glenview Trust Co now owns 4,404 shares of the biopharmaceutical company’s stock valued at $2,746,000 after buying an additional 436 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Positive Sentiment: The FDA approved Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder that causes abnormal bone growth. In a 56-week Phase 3 trial, the approved dose reduced disease-related bone formation, giving Regeneron a new commercial opportunity and strengthening its rare-disease pipeline. However, the small patient population likely limits the drug’s near-term earnings contribution. Can Regeneron’s Rare-Disease Win Move the Earnings Needle?
Neutral Sentiment: An investor letter highlighted Regeneron’s response to mixed results from its melanoma drug trials, including adjustments to its development strategy. The update offers limited new information but underscores the importance of replacing potential value lost from the failed program. Regeneron Adjusts Course Amid Mixed Results in Melanoma Drug Trials
Negative Sentiment: Several law firms announced or promoted a securities-fraud class action related to disclosures surrounding Regeneron’s failed Phase 3 melanoma trial. The failure reportedly erased approximately $11 billion in market capitalization and prompted allegations that investors were misled about the program. The repeated notices, all citing a September 14, 2026 lead-plaintiff deadline, add reputational and potential litigation-cost risks, although they do not represent a finding of wrongdoing. Regeneron Securities Fraud Class Action Filed Faruqi Shareholder Notice

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $794.19 on Friday. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The firm has a market cap of $81.77 billion, a PE ratio of 19.63, a P/E/G ratio of 1.35 and a beta of 0.22. The business has a 50 day moving average of $717.52 and a 200-day moving average of $718.38. Regeneron Pharmaceuticals, Inc. has a 12-month low of $541.00 and a 12-month high of $847.00.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same period last year, the company posted $12.81 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 16.7% compared to the same quarter last year. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be given a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. The trade was a 31.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $320,000.00. Following the completion of the transaction, the director directly owned 603 shares in the company, valued at $482,400. This trade represents a 39.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,400 shares of company stock worth $1,090,030 in the last ninety days. Company insiders own 6.97% of the company’s stock.

Analysts Set New Price Targets

REGN has been the subject of a number of analyst reports. JPMorgan Chase & Co. lowered their price target on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research report on Monday, May 18th. Piper Sandler cut their price objective on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a report on Thursday, July 9th. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a research note on Tuesday, July 7th. Truist Financial upped their target price on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Finally, BMO Capital Markets lowered their target price on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a report on Monday, May 18th. Fifteen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $800.36.

Check Out Our Latest Stock Report on REGN

Regeneron Pharmaceuticals Profile

(Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.